Sorafenib improves survival of -mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party.
作者信息
Bazarbachi Ali, Labopin Myriam, Battipaglia Giorgia, Djabali Azedine, Passweg Jakob, Socié Gerard, Forcade Edouard, Blaise Didier, Chevallier Patrice, Orvain Corentin, Cornelissen Jan J, Arcese William, Chantepie Sylvain, Hashaishi Khowla, El Cheikh Jean, Medinger Michael, Esteve Jordi, Nagler Arnon, Mohty Mohamad
机构信息
Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
Department of Cell Biology, Anatomy and Physiological Sciences, American University of Beirut, Beirut, Lebanon.
出版信息
Haematologica. 2019 Sep;104(9):e398-e401. doi: 10.3324/haematol.2018.211615. Epub 2019 Feb 21.
Abstract
摘要
相似文献
1
Sorafenib improves survival of -mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party.
Haematologica. 2019 Sep;104(9):e398-e401. doi: 10.3324/haematol.2018.211615. Epub 2019 Feb 21.
2
Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
Cancer. 2020 Jan 15;126(2):344-353. doi: 10.1002/cncr.32534. Epub 2019 Oct 3.
3
Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.
Cancer. 2018 May 1;124(9):1954-1963. doi: 10.1002/cncr.31295. Epub 2018 Mar 6.
4
Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation.
Biol Blood Marrow Transplant. 2019 Aug;25(8):1674-1681. doi: 10.1016/j.bbmt.2019.04.018. Epub 2019 Apr 19.
5
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With -Internal Tandem Duplication Mutation (SORMAIN).
J Clin Oncol. 2020 Sep 10;38(26):2993-3002. doi: 10.1200/JCO.19.03345. Epub 2020 Jul 16.
6
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.
Br J Haematol. 2016 Nov;175(3):496-504. doi: 10.1111/bjh.14260. Epub 2016 Jul 19.
7
Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update.
Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):506-508. doi: 10.1016/j.clml.2019.04.004. Epub 2019 Apr 18.
8
Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.
Clin Lymphoma Myeloma Leuk. 2015 May;15(5):298-302. doi: 10.1016/j.clml.2014.12.005. Epub 2014 Dec 12.
9
Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.
Cancer. 2019 Nov 1;125(21):3755-3766. doi: 10.1002/cncr.32387. Epub 2019 Jul 16.
10
High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
Eur J Haematol. 2016 Jun;96(6):629-36. doi: 10.1111/ejh.12647. Epub 2015 Sep 21.
引用本文的文献
1
T-cell acute lymphoblastic leukaemia: subtype prevalence, clinical outcome, and emerging targeted treatments.
Leukemia. 2025 Apr 17. doi: 10.1038/s41375-025-02599-2.
2
Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link?
Cancers (Basel). 2024 Dec 29;17(1):72. doi: 10.3390/cancers17010072.
3
Accelerating CAR-T Cell Therapies with Small-Molecule Inhibitors.
BioDrugs. 2025 Jan;39(1):33-51. doi: 10.1007/s40259-024-00688-9. Epub 2024 Nov 26.
4
The Immunomodulatory Effect of Different FLT3 Inhibitors on Dendritic Cells.
Cancers (Basel). 2024 Nov 4;16(21):3719. doi: 10.3390/cancers16213719.
5
Sorafenib maintenance after allogeneic stem cell transplantation in patients with FLT3+ AML receiving midostaurin during induction and consolidation: a retrospective analysis.
Front Oncol. 2024 Sep 19;14:1441254. doi: 10.3389/fonc.2024.1441254. eCollection 2024.
6
Prognostic insights and immune microenvironment delineation in acute myeloid leukemia by ferroptosis-derived signature.
Heliyon. 2024 Mar 15;10(6):e28237. doi: 10.1016/j.heliyon.2024.e28237. eCollection 2024 Mar 30.
7
Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.
Trials. 2023 Sep 15;24(1):591. doi: 10.1186/s13063-023-07421-x.
8
Post-transplant maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation harmonizing multiple therapeutic modalities including targeted therapy, immunotherapy and cellular therapy.
Int J Hematol. 2023 Jul;118(1):1-17. doi: 10.1007/s12185-023-03614-x. Epub 2023 May 22.
9
Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Bone Marrow Transplant. 2023 Jul;58(7):784-790. doi: 10.1038/s41409-023-01961-1. Epub 2023 Apr 11.
10
Treatment options for acute myeloid leukemia patients aged <60 years.
Front Oncol. 2022 Oct 5;12:897220. doi: 10.3389/fonc.2022.897220. eCollection 2022.
本文引用的文献
1
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.
Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12.
2
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation.
Eur J Cancer. 2017 Nov;86:233-239. doi: 10.1016/j.ejca.2017.09.016. Epub 2017 Oct 18.
3
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
N Engl J Med. 2017 Aug 3;377(5):454-464. doi: 10.1056/NEJMoa1614359. Epub 2017 Jun 23.
4
Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.
Cancer. 2017 Aug 1;123(15):2867-2874. doi: 10.1002/cncr.30680. Epub 2017 Apr 7.
5
Inhibition of FLT3 in AML: a focus on sorafenib.
Bone Marrow Transplant. 2017 Mar;52(3):344-351. doi: 10.1038/bmt.2016.251. Epub 2016 Oct 24.
6
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.
Br J Haematol. 2016 Nov;175(3):496-504. doi: 10.1111/bjh.14260. Epub 2016 Jul 19.
7
Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation.
Blood. 2015 Oct 22;126(17):2062-9. doi: 10.1182/blood-2015-06-651562. Epub 2015 Sep 8.
8
Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.
Clin Lymphoma Myeloma Leuk. 2015 May;15(5):298-302. doi: 10.1016/j.clml.2014.12.005. Epub 2014 Dec 12.
9
Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.
Biol Blood Marrow Transplant. 2014 Dec;20(12):2042-8. doi: 10.1016/j.bbmt.2014.09.007. Epub 2014 Sep 17.
10
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
Blood. 2013 Jun 6;121(23):4655-62. doi: 10.1182/blood-2013-01-480228. Epub 2013 Apr 23.
Zotero 插件